Download Free Medical Metabolic Syndrome PowerPoint Presentation

Metabolic Syndrome PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Atherosclerosis, which is titled "Metabolic Syndrome", to know about the constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD) and diabetes mellitus.

Tags : Atherosclerosis, Metabolic Syndrome, metabolic abnormalities, risk, cardiovascular disease, CVD, diabetes mellitus

Published on : Jun 02, 2021 | Views : 5092 | Downloads : 46

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

METABOLIC SYNDROME Dr. Kauser Usman (MD) Associate Professor Department of Medicine King George’s Medical University, Lucknow
Slide 2-

International Diabetes Federation Definition: Abdominal obesity plus two other components: elevated BP, low HDL, elevated TG, or impaired fasting glucose
Slide 3-

Definition Constellation of metabolic abnormalities that confer increased risk of cardiovascular disease(CVD) and diabetes mellitus.
Slide 4-

Alternative names Metabolic syndrome Syndrome X Insulin resistance syndrome Deadly quartet Reaven’s syndrome
Slide 5-

The major features of metabolic syndrome include Central obesity Hypertrilgyceridemia Low high density lipoprotein (HDL) Hyperglycemia hypertension
Slide 6-

EPIDEMIOLOGY Prevalence increases with age Greater industrialization and urbanization Increase in waist circumference is found predominantly in women. Fasting TG>150 mg/dl and hypertension more likely in men.
Slide 7-

Risk factors Overweight/ obesity- central (key feature) Sedentary lifestyle Predictor of CVd events and associted mortality Associated with central obesity, TG’s, HDL, BP, glucose intolerance Aging- prevalence increases with age Diabetes mellitus- approx. 75% of T2DM or IGT have metabolic syndrome Coronary heart disease- 50% of CHD patients have metabolic syndrome About 1/3rd of MS patients have premature CAD Lipodystrophy- both genetic or acquired have severe insulin resistance
Slide 8-

CLINICAL FEATURES Usually asymptomatic and a high index of suspicion is needed for diagnosis Examination - Increased waist circumference Increased Blood Pressure Lipoatrophy Acanthosis nigricans/ skin tags Should alert to search for other abnormalities
Slide 9-

ppt slide no 9 content not found
Slide 10-

Other associated conditions Cardiovascular disease increased risk for new onset CVD, ischemic stroke, PVD Type 2 diabetes mellitus increased risk by 3-5 folds NAFLD and/or NASH Hyperuricemia PCOS- prevalence 40-50% OSA- commonly associated with obesity, HTN & insulin resistance (CPAP improves insulin sensitivity)
Slide 11-

ppt slide no 11 content not found
Slide 12-

IDF criteria Waist circumference: ≥90 in males ≥80 in females Plus two or more of the following Hypertriglyceridemia: ≥150 TG’s or specific medication Low HDL cholesterol: <40(M) and <50(F) or specific medication Hypertension: blood pressure ≥130 mm systolic or ≥85 mm diastolic or specific medication Fasting plasma glucose: ≥100 mg/dl or specific medication or previously diagnosed T2DM
Slide 13-

IDF criteria *Diagnosis is established when 3 of these risk factors are present. †Abdominal obesity is more highly correlated with metabolic risk factors than is BMI. ‡Some men develop metabolic risk factors when circumference is only marginally increased.
Slide 14-

IDF criteria contd…
Slide 15-

IDF criteria contd…
Slide 16-

Pathogenesis Insulin resistance Increased waist circumference Dyslipidemia Glucose intolerance Hypertension Decreased adiponectin levels
Slide 17-

Pathogenesis contd… Central obesity is the keystone for pathogenesis of “METABOLIC SYNDROME” Central obesity leads to insulin resistance. Various factors that play a role in pathogenesis includes: IL-1, IL-6, IL-18 Resistin TNF-alpha CRP Adiponectin an anti inflammatory cytokine is reduced in metabolic syndrome.
Slide 18-

Pathogenesis contd…
Slide 19-

Pathogenesis contd… Impaired insulin mediated glucose uptake Toxic injury to pancreatic islets Increased insulin resistance Hyperglycemia Type 2 DM Insulin resistance pp/fasting hyperinsulinemia Lipolysis by LPL Abundance of FFA’s
Slide 20-

Pathogenesis contd…
Slide 21-

Pathogenesis contd…
Slide 22-

How to diagnose? IDF criteria H/o symptoms of OSA in all patients H/o PCOS in premenopausal women Family H/o CVD and DM Waist circumference and BP measurement Laboratory investigations Fasting lipid profile and fasting glucose hs-CRP, fibrinogen, uric acid, urinary microalbumin LFT for NAFLD Sleep study for OSA Testosterone, FSH, LH for PCOS
Slide 23-

TREATMENT
Slide 24-

Weight reduction- include a combination of caloric restriction, increased physical activity, and behavior modification. LIFESTYLE MODIFICATIONS
Slide 25-

~500 kcal restriction daily equates to weight reduction of 1 lb per week. Diets restricted in carbohydrate typically provide a rapid initial weight loss. Adherence to the diet is more important than which diet is chosen. A high-quality diet— i.e., enriched in fruits, vegetables, whole grains, lean poultry, and fish—should be encouraged to provide the maximum overall health benefit. DIET---
Slide 26-

What to do..?
Slide 27-

PHYSICAL ACTIVITY- 60–90 min of daily activity (At least 30 min.) Gradual increases in physical activity should be encouraged to enhance adherence and avoid injury. Some high-risk patients should undergo formal cardiovascular evaluation before initiating an exercise program. Physical activity could be formal exercise such as jogging, swimming, or tennis or routine activities, such as gardening, walking, and housecleaning.
Slide 28-

Appetite suppressants-phentermine and sibutramine. Absorption inhibitors-Orlistat Bariatric surgery is also an option for patients with BMI >40 kg/m2 or >35 kg/m2 with comorbidities. OBESITY
Slide 29-

A fasting triglyceride value of <150 mg/dL is recommended. A weight reduction of >10% is necessary to lower fasting triglycerides. A fibrate (gemfibrozil or fenofibrate) is the drug of choice to lower fasting triglycerides and typically achieve a 35–50% reduction. Other drugs that lower triglycerides include statins, nicotinic acid, and high doses of omega-3 fatty acids. TRIGLYCERIDES
Slide 30-

For rise in HDL cholesterol, weight reduction is an important strategy. Nicotinic acid is the only currently available drug with predictable HDL cholesterol-raising properties. Statins, fibrates, and bile acid sequestrants have modest effects (5–10%), and there is no effect on HDL cholesterol with ezetimibe or omega-3 fatty acids. HDL Cholesterol
Slide 31-

LDL Cholesterol For patients with the metabolic syndrome and diabetes, LDL cholesterol should be reduced to <100 mg/dL.
Slide 32-

BLOOD PRESSURE The direct relationship between blood pressure and all-cause mortality rate has been well established. Best choice for the first antihypertensive should usually be an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker. In all patients with hypertension, a sodium-restricted diet enriched in fruits and vegetables and low-fat dairy products should be advocated.
Slide 33-

Insulin resistance is the primary Patho-physiologic mechanism for the metabolic syndrome. Several drug classes [biguanides, thiazolidinediones (TZDs)] increase insulin sensitivity. Both metformin and TZDs enhance insulin action in the liver and suppress endogenous glucose production. TZDs, but not metformin, also improve insulin-mediated glucose uptake in muscle and adipose tissue. Benefits of both drugs have also been seen in patients with NAFLD and PCOS, and the drugs have been shown to reduce markers of inflammation and small dense LDL. INSULIN RESISTANCE
Slide 34-

In patients with the metabolic syndrome and Type 2 diabetes, aggressive glycemic control decreases cardiovascular risk.. In patients with IFG without a diagnosis of diabetes, a lifestyle intervention has been shown to reduce the incidence of Type 2 diabetes. Metformin has also been shown to reduce the incidence of diabetes, although the effect was less than that seen with lifestyle intervention. GLYCEMIC CONTROL
Slide 35-

Most patients with metabolic syndrome exhibit a prothrombotic state characterized by elevations of plasminogen activator inhibitor-1 and fibrinogen. Use of low dose aspirin can be recommended for patients with metabolic syndrome, who have a high CV risk, those with overt type 2 diabetes mellitus, or atherosclerotic cardiovascular diseases. Metabolic syndrome frequently is accompanied by a pro-inflammatory state, characterized by increased CRP levels. No specific treatment available. PROTHROMBOTIC & PROINFLAMMATORY STATE
Slide 36-

ppt slide no 36 content not found
Slide 37-

Que1- Metabolic syndrome comprises of all except Hypertension Dyslipidemia Type 1 diabetes mellitus Central/upper body obesity
Slide 38-

Que2- All of the following parameters are included in the diagnostic criteria of metabolic syndrome except Serum HDL levels Serum triglyceride levels Serum LDL levels Fasting plasma glucose
Slide 39-

Que3- Various risk factors for metabolic syndrome includes all except Increasing Age Obesity Congenital heart disease Sedentary life style
Slide 40-

Que4- Metabolic syndrome is associated with increased risk of all except Cardiovascular disease Type 2 diabetes mellitus Hypothyroidism Non-alcoholic fatty liver disease
Slide 41-

Que5- Most effective strategy in management of metabolic syndrome is Use of Insulin sensitizing agents Lifestyle changes Treatment of Hyperlipdemia Treatment of hypertension
Slide 42-

Que6- Metabolic syndrome is also known as all except: Insulin resistance syndrome Syndrome X Polycystic ovarian syndrome Reaven syndrome
Slide 43-

Que7- Basic pathophysiology associated with the pathogenesis of metabolic syndrome is Hypertension Hyperlipidemia Insulin Resistance Hyperglycemia
Slide 44-

Que8- According to IDF criteria for diagnosis of metabolic syndrome strike the odd one out- Central obesity: Waist circumference >90 cm (M), >80cm (F) Triglycerides ≤150 mg/dL Blood pressure ≥130 mm systolic or ≥85 mm diastolic or specific medication Fasting plasma glucose ≥100 mg/dL or previously diagnosed Type 2 diabetes
Slide 45-

Que9- Acanthosis nigricans is a feature of Obesity Insulin resistance Polycystic ovarian syndrome Dyslipidemia
Slide 46-

Que10- Which of the following conditions is not associated with metabolic syndrome Non-alcohlolic fatty liver disease Hyperuricemia Obstructive sleep apnea Polycystic kidney disease